Prime Medicine’s strategy to efficiently develop Prime Editors for genetic liver diseases. The Wilson’s Disease treatment landscape, patient experience and global market opportunity, for which there ...
Revenue reaches new all-time high Record low C1 cash costs1 Adjusted EBITDA1 sets quarterly record, up last four quarters Capstone Copper Corp. ("Capstone" or the "Company") (TSX: CS) (ASX: CSC) ...
Revenue reaches new all-time high Record low C1 cash costs1 Adjusted EBITDA1 sets quarterly record, up last four quarters VANCOUVER, British ...
Travere Therapeutics, Inc. (NASDAQ: TVTX) today reported its third quarter 2025 financial results and provided a corporate update.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback